TEORAM

Keyword: Gene editing

Intellia's Nex-z MAGNITUDE Trial: In-Depth Analysis

Intellia Therapeutics' MAGNITUDE trial, evaluating nexiguran ziclumeran (nex-z) for transthyretin amyloidosis (ATTR), has released updated data. This analysis examines the trial's progress, potential implications, and c…

Analysis: Tech Tycoon's £10bn Oxford Investment

A tech tycoon's proposed £10 billion investment in Oxford is analyzed for its potential impact on the UK's tech sector and its possible political implications, particularly for the Labour party. The investment's scale a…